FOXO Technologies Announces Acquisition of 4 U.S. Blood Centers

What Happened

• On July 29, 2026, FOXO Technologies, Inc. (FOXO) disclosed in a Form 8-K that its subsidiary, Vector BioSource, Inc., has entered into a definitive agreement to acquire four U.S.-based blood collection centers from Grifols Bio Supplies, Inc., a U.S. subsidiary of Grifols S.A. The company furnished a press release announcing the transaction as Exhibit 99.1 to the 8-K.

Key Details

• Date filed: July 29, 2026 (Form 8-K, Regulation FD disclosure).
• Buyer: Vector BioSource, Inc. (FOXO subsidiary).
• Seller: Grifols Bio Supplies, Inc. (U.S. subsidiary of Grifols S.A.).
• Transaction scope: acquisition of four U.S.-based blood collection centers; the 8-K furnishes a press release but does not disclose purchase price or detailed financial terms.

Why It Matters

• This is a strategic acquisition that expands Vector BioSource’s blood collection footprint and could affect FOXO’s future service capacity and revenue mix.
• The 8-K provides initial disclosure but lacks financial details and closing timing; investors should watch for follow-up filings and press releases for purchase price, financing, integration plans, and expected impact on FOXO’s financial results.